Literature DB >> 1386916

Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones.

S W Davies1, K Beardsall.   

Abstract

Selective neuronal death is a prominent feature of human neurodegenerative disease both of genetic and idiopathic origin. Huntington's disease is characterised by the selective degeneration of striatal projection neurones, with the relative preservation of a variety of interneurones. The ability of the endogenous excitotoxin, quinolinic acid, to produce a pattern of selective neuronal cell death was investigated using immunocytochemical and histochemical techniques. We find that the large striatal, cholinergic interneurones are relatively spared, and that this sparing can be enhanced by the co-administration of the neurotrophin, nerve growth factor (NGF). Further, a single co-injection of NGF will selectively prevent both the cell death and morphological changes that occur within cholinergic cells when assessed 2 weeks later. These results suggest that an interaction between growth factors and excitotoxins can dramatically modify patterns of selective neuronal death.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386916     DOI: 10.1016/0304-3940(92)90092-l

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.

Authors:  K D Anderson; N Panayotatos; T L Corcoran; R M Lindsay; S J Wiegand
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells.

Authors:  A Martínez-Serrano; A Björklund
Journal:  J Neurosci       Date:  1996-08-01       Impact factor: 6.167

3.  Differential susceptibility to neurotoxicity mediated by neurotrophins and neuronal nitric oxide synthase.

Authors:  A F Samdani; C Newcamp; A Resink; F Facchinetti; B E Hoffman; V L Dawson; T M Dawson
Journal:  J Neurosci       Date:  1997-06-15       Impact factor: 6.167

4.  Cellular hybridization for BDNF, trkB, and NGF mRNAs and BDNF-immunoreactivity in rat forebrain after pilocarpine-induced status epilepticus.

Authors:  R Schmidt-Kastner; C Humpel; C Wetmore; L Olson
Journal:  Exp Brain Res       Date:  1996       Impact factor: 1.972

5.  Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.

Authors:  J H Kordower; V Charles; R Bayer; R T Bartus; S Putney; L R Walus; P M Friden
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

6.  TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin.

Authors:  T Sobreviela; D O Clary; L F Reichardt; M M Brandabur; J H Kordower; E J Mufson
Journal:  J Comp Neurol       Date:  1994-12-22       Impact factor: 3.215

7.  Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease.

Authors:  Dwaine F Emerich; David J Mooney; Hannah Storrie; Rangasamy Suresh Babu; Jeffrey H Kordower
Journal:  Neurotox Res       Date:  2009-07-09       Impact factor: 3.911

Review 8.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.